TMCnet - World's Largest Communications and Technology Community



Research and Markets: Gaucher's Disease - Pipeline Review, H1 2014
[July 03, 2014]

Research and Markets: Gaucher's Disease - Pipeline Review, H1 2014

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Gaucher's Disease - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects.

Reasons to buy

  • Provide strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • Genzyme Corporation
  • Sangamo BioSciences, Inc.
  • Shire Plc
  • Amicus Therapeutics, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Protalix BioTherapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • greenovation Biotech GmbH
  • Neuraltus Pharmaceuticals, Inc.
  • Biosidus S.A.
  • ExSAR Corporation
  • Bioorganic Research and Services S.A.
  • Dong-A Socio Holdings Co Ltd

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy